COVID-19: A Comprehensive Overview

Main Article Content

Hira Amir
Ally Prebtani

COVID-19, pandemic


Coronaviruses are important pathogens reported in humans and animals. A novel coronavirus, formally known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was identified as a cause of pneumonia cases in Wuhan, China, in late 2019. Since its outbreak in China, it has disproportionately affected many countries. Coronavirus disease 2019 (COVID-19) was officially declared a pandemic on March 11, 2020 and remains a global concern. A spectrum of disease severity has been reported with a variable course of illness from mild upper respiratory symptoms, pneumonia to acute respiratory distress syndrome (ARDS), shock, multiorgan dysfunction and death. The worldwide dissemination of the virus justifies the global efforts in identifying potential treatment strategies and a vaccine for improved clinical and long-term outcomes. This article will reflect on human viral replication and transmission, variable clinical presentation, assessment, treatment and discussion of complications. Isolation precautions according to infection prevention and control including protective apparel will be discussed with emphasis on criteria for discontinuation of transmission precaution.


Les coronavirus sont des agents pathogènes importants signalés chez les humains et les animaux. Un nouveau coronavirus, officiellement connu sous le nom de coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2), a été identifié comme une cause de cas de pneumonie à Wuhan, en Chine, à la fin de 2019. Depuis son apparition en Chine, il a touché de nombreux pays de manière disproportionnée. La maladie à coronavirus 2019 (COVID-19) a été officiellement déclarée pandémie le 11 mars 2020 et reste une préoccupation mondiale. Un éventail de gravité de la maladie a été signalé, avec une évolution variable de la maladie allant de symptômes respiratoires supérieurs légers, de la pneumonie au syndrome de détresse respiratoire aiguë (SDRA), au choc, au dysfonctionnement de plusieurs organes et à la mort. La diffusion mondiale du virus justifie les efforts mondiaux visant à identifier des stratégies de traitement potentielles et un vaccin pour améliorer les résultats cliniques et à long terme. Cet article se penchera sur la réplication et la transmission du virus chez l'homme, la présentation clinique variable, l'évaluation, le traitement et la discussion des complications. Les précautions d'isolement en fonction de la prévention et du contrôle de l'infection, y compris les vêtements de protection, seront examinées en mettant l'accent sur les critères d'interruption de la précaution de transmission.



Abstract 104 | pdf Downloads 15 HTML Downloads 5


1. Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiol Reviews 2015 Apr;28(2):465–522.
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020 Mar;579(7798):270–3.
3. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020 Apr;382(17):1653–9. doi/10.1056/ NEJMsr2005760
4. World health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Available from: implications-for-ipc-precaution-recommendations [Accessed 11 May 2020]
5. Kenneth McIntosh. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. 2020. Available from:
epidemiology-virology-clinical-features-diagnosis-and-prevention [Accessed 12 May 2020]
6. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020 Apr;1–5.
7. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med 2020 Apr.
8. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the Basic Reproduction Number (R0). Emerg Infect Dis J 2019 Jan;25(1):1-4.
9. Centre of Infectious Disease Research and Policy. COVID-19: The CIDRAP Viewpoint. Available from: public/downloads/cidrap-covid19-viewpoint-part1_0.pdf [Accessed 11 May 2020]
10. Ontario Agency for Health Protection and Promotion (Public health Ontario). Infection Prevention and Control recommendations for use of personal protective equipment for care of individuals with suspect or confirmed COVID-19. Toronto, Ontario. 2020. Available from: [Accessed 12 May 2020]
11. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Available from: https://www.who. int/publications-detail/clinical-management-of-severe-acute-respiratory-
infection-when-novel-coronavirus-(ncov)-infection-is-suspected [Accessed 15 April 2020]
12. Worldometer. Coronavirus Mortality Rate (COVID-19). Available from:
[Accessed 11 May 2020]
13. Government of Ontario Ministry of Health and Long-Term Care. MERS-
CoV (Novel Coronavirus) - Ministry Programs - Health Care Professionals- MOHLTC. Available from: [Accessed 10 May 2020]
14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 1;395(10223):497–506.
15. Patanavanich R, Glantz SA. Smoking is Associated with COVID-19 Progression: A Meta-Analysis. medRxiv [Internet]. 2020 Apr;2020.04.13.20063669. doi/10.1101/2020.04.13.20063669
16. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 73. 2020. Available from: coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf [Accessed
10 May 2020]
17. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020 May;39(5):405–7.
18. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020 Apr. doi/10.1101/2020.03.30.20047365
19. World Health Organization . Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance. 2020. Available from: [Accessed 29 April 2020]
20. World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance. 2020. Available from: [Accessed 25 April 2020]
21. Hamilton Health Sciences. COVID-19: Safety, Screening & Reporting.
2020. Available from: [Accessed 12 May 2020]
22. Chuen V, Said H, Shell J, Plaxton W, Ciccotelli W. Diagnosis of COVID-19 by Bronchoalveolar Lavage after Two Negative Nasopharyngeal Swabs. Can J Gen Intern Med 2020 Apr 8;15(2):5–7.
23. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal Swab Specimen. N Engl J Med 2020 Apr. doi: 10.1056/NEJMvcm2010260
24. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. CHEST 2020 Apr. doi:
25. Public Health Ontario. Review of “Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020”. 2020. Available from:
documents/ncov/research-eurosurveill-differential-diagnosis.pdf?la=en [Accessed 13 May 2020]
26. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intens Care Med 2020 May;46(5):854–87. doi:10.1007/s00134-020-06022-5
27. Poston JT, Patel BK, Davis AM. Management of Critically Ill Adults With COVID-19. JAMA 2020 May;323(18):1839–41.
28. Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou
A, et al. Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. N Engl J Med 2010 Sep;363(12):1107–16. NEJMoa1005372
29. Ye Z, Rochwerg B, Wang Y, Adhikari NK, Murthy S, Lamontagne F, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ 2020 Apr. doi:10.1503/cmaj.200648
30. Caputo ND, Strayer RJ, Levitan R. Early Self-Proning in Awake, Non-intubated Patients in the Emergency Department: A Single ED’s Experience during the COVID-19 Pandemic. Acad Emerg Med 2020 Apr;27(5):375–78.
31. Calvillo-Argüelles O, Ross HJ. Cardiac considerations in patients with COVID-19. CMAJ 2020 May. doi/10.1503/cmaj.200562
32. Lee SG, Fralick M, Sholzberg M. Coagulopathy associated with COVID-19. CMAJ 2020 May. doi:10.1503/cmaj.200685
33. Farkas J. COVID-19 - EMCrit Project. The Internet Book of Critical Care. 2020. Available from: [Accessed 01 May 2020]
34. Arya A, Buchman S, Gagnon B, Downar J. Pandemic palliative care: beyond ventilators and saving lives. CMAJ 2020 Apr;192(15):400–4.
35. Canada Health. Vaccines and treatments for COVID-19: List of all COVID 19 clinical trials authorized by Health Canada. 2020. Available from: https:// [Accessed 13 May 2020]
36. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020 Apr;323(16):1582–9.
37. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020 Apr;323(16):1561 2.
38. National Institute of Allergy and Infectious Diseases. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH. 2020. Available from: [Accessed 09 May 2020]
39. Bombardini T, Picano E. Angiotensin-converting enzyme 2 as the molecular bridge between epidemiologic and clinical features of COVID-19. Can J Cardiol 2020 May;36(5):784.e1-784.e2.
40. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res 2020 Apr.
41. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020 Apr;382(17):1653–9. doi:10.1056/ NEJMsr2005760
42. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020 May.
43. Jarcho JA, Ingelfinger JR, Hamel MB, D’Agostino RB, Harrington DP.
Inhibitors of the renin–angiotensin–aldosterone system and Covid-19. N Engl J Med 2020 May.
44. Canadian Cardiovascular Society. Guidance from the CCS COVID-19 rapid response team. 2020. Available from: Images_2020/CCS_CHFS_Update_COVID__CV_medications_Mar20.pdf
[Accessed 25 April 2020]
45. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020 Jul;395(10226):809–15.
46. Maxwell C, McGeer A, Tai KFY, Sermer M. No. 225-Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS). Jo Obstet Gynaecol Canada 2017 Aug;39(8):130–7.
47. Society of Obstetrics and Gynecology. Updated SOGC Committee Opinion – COVID-19 in Pregnancy. 2020. Available from: content/featured-news/Updated-SOGC-Committee-Opinion__COVID-19-in-Pregnancy.aspx [Accessed 02 May 2020]
48. United States Department of Health and Human Services - AIDSinfo. Interim Guidance for COVID-19 and Persons with HIV COVID-19 and Persons with HIV. Available from: [Accessed 20 April 2020]
49. O’donnell J, Sharif K, Emery P, Bridgewood C, Mcgonagle D. The Immune Mechanisms of Pulmonary Intravascular Coagulopathy in COVID-19
Pneumonia. 2020 May. doi:
50. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020 Apr. doi:10.1001/jama.2020.6825
51. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020 May. doi:
52. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with covid-19 in Wuhan, China. JAMA Cardiol 2020 Mar. doi:10.1001/jamacardio.2020.0950
53. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China.
JAMA Neurol 2020 Apr. doi:10.1001/jamaneurol.2020.1127
54. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of covid-19 in the young. New N Engl J Med 2020 Apr.
55. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic reatures in severe SARS-CoV-2 infection. N Engl J Med 2020 Apr.
56. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T,
et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Res [Internet] 2020 Jul;191:9–14.
57. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res 2020 Apr. doi: 10.1016/ j.thromres.2020.04.013
58. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020 Apr.
59. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thrombosis Haemost 2020 Mar;18(5):1094–9.
60. Burzynski LC, Humphry M, Pyrillou K, Wiggins KA, Chan JNE, Figg N, et al. The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin. Immunity 2019 Apr;50(4): 1033-1042.e6.
61. Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology 2020 Apr. doi: j.gastro.2020.03.055.
62. Micheal W. Smith. Complications of Coronavirus (COVID-19). Available from: [Accessed 04 May 2020]
63. Micheal W. Smith. Coronavirus Recovery. Available from: [Accessed 11 May 2020]
64. World Health organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 3 March 2020. Available from: https://www. [Accessed 15 may 2020]
65. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020 Apr;323(16):1574–81.
66. World Health Organization. Advice for public. 2020. Available from: https:// [Accessed 12 May 2020]
67. Canada Public Health Agency. COVID-19: About non-medical masks and face coverings. 2020. Available from: about-non-medical-masks-face-coverings.html [Accessed 10 May 2020]
68. World Health Organization. Advice on the use of masks in the context of COVID-19. 2020. Available from: [Accessed 05 May 2020]
69. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). 2020. Available from: [Accessed 29 April 2020]
70. Canada Public Health Agency. How to care for a person with COVID-19 at home: Advice for caregivers [Internet]. 2020. Available from: https://www. [Accessed 30 April 2020]
71. Centre for Disease Control. Guidance for the Selection and Use of Personal Protective Equipment (PPE) in Healthcare Settings. Available from: https:// [Accessed 11 May 2020]
72. Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19. Available from: https://www. [Accessed 15 April 2020]
73. London Health Sciences Centre. Guidelines Adult Critical care for Aerosol Generating Medical Procedures (AGMP) for Failed ARI Screen or Unable to Assess or Confirmed COVID-19. 2020. Available from: https://www.lhsc. [Accessed 20 April 2020]
74. Ministry of Health Ontario. Ministry of Health COVID-19 Quick Reference Public Health Guidance on Testing and Clearance. 2020. Available from: coronavirus/2019_guidance.aspx#guidance [Accessed 14 May 2020]
75. Centre for Disease Control and Prevention. Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance). 2020. Available from: https:// html [Accessed 15 April 2020]